Home / Business and Economy / Sun Pharma Eyes Strategic M&A for Global Growth
Sun Pharma Eyes Strategic M&A for Global Growth
1 Feb
Summary
- Sun Pharma will adopt a disciplined approach to mergers and acquisitions.
- The company is interested in selling innovative medicines globally.
- Emerging markets are targeted for smaller acquisitions to gain scale.
Sun Pharmaceutical Industries, India's largest drug maker, is adopting a disciplined strategy for mergers and acquisitions. The company will pursue acquisitions only if they strengthen long-term strategic capabilities. Its primary interest lies in selling innovative medicines globally.
For emerging markets, Sun Pharma is considering smaller, 'tuck-in' acquisitions to integrate with existing businesses and achieve greater scale. This approach complements their focus on organic growth as an attractive investment opportunity for shareholders.
The pharmaceutical giant is also evaluating the biosimilars space and geographical expansion in emerging markets. North America remains a key focus, particularly for innovative medicines, despite recent speculative media reports about potential acquisitions. The company stressed financial prudence, willing to raise debt if necessary but ensuring effective management of any acquired entities without diluting focus on organic growth.
